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MacroorchidismFragile X syndrome (FXS) is the most common form of inherited mental retardation and is one of the few known
genetic causes of autism. FXS results from the loss of Fmr1 gene function; thus, Fmr1 knockout mice provide a
model to study impairments associated with FXS and autism and to test potential therapeutic interventions. The
inhibitory serine phosphorylation of glycogen synthase kinase-3 (GSK3) is lower inbrain regions of Fmr1 knockout
mice thanwild-typemice and theGSK3 inhibitor lithiumrescues several behavioral impairments inFmr1knockout
mice. Therefore, we examined if the serine phosphorylation of GSK3 in Fmr1 knockout mice also was altered
outside the brain and if administration of lithium ameliorated the macroorchidism phenotype. Additionally, since
GSK3 regulates numerous functions of the immune system and immune alterations have been associated with
autism, we tested if immune function is altered in Fmr1 knockout mice. The inhibitory serine phosphorylation of
GSK3was signiﬁcantly lower in the testis and liver of Fmr1knockoutmice thanwild-typemice, and chronic lithium
treatment reduced macroorchidism in Fmr1 knockout mice. No alterations in peripheral immune function were
identiﬁed in Fmr1 knockout mice. However, examination of glia, the immune cells of the brain, revealed reactive
astrocytes in several brain regions of Fmr1 knockoutmice and treatment with lithium reduced this in the striatum
and cerebellum. These results provide further evidence of the involvement of dysregulated GSK3 in FXS, and
demonstrate that lithium administration reduces macroorchidism and reactive astrocytes in Fmr1 knockoutmice.S, Fragile X syndrome; Fmr1,
etardation protein; GFAP, glial
se-3; IFNγ, interferon-γ; IL-6,
otropic glutamate receptor 5;
+1 205 934 2500.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Fragile X syndrome (FXS) is caused by functional loss of the fragile X
mental retardation1 (Fmr1) gene on theX chromosome, resulting in lack
of the gene product, fragile X mental retardation protein (FMRP), an
RNA binding protein that regulates translation [1,2]. FXS is the most
common cause of inheritedmental retardation and is the ﬁrst identiﬁed
autism-related gene because FXS patients have many characteristics
commonly associated with autism spectrum disorders (ASDs), such as
developmental delays, communication impairments, and anxiety [2–9].
These conditions are modeled in Fmr1 knockout mice [10] that display
several phenotypes of FXS andASDs [11–20]. Thus, Fmr1 knockoutmice
provide an important animal model to study characteristics of FXS as
well as autistic traits, and to test potential therapeutic interventions.
Studies of pharmacological interventions in Fmr1 knockout mice have
identiﬁed therapeutic effects of antagonists of metabotropic glutamate
receptor 5 (mGluR5) [1,21] and of lithium [13,14,20], an inhibitor of
glycogen synthase kinase-3 (GSK3) [22,23].FXS and autism are generally considered to be neuronal disorders
because of the predominant behavioral and cognitive abnormalities.
However, neuronal function can be modiﬁed by many types of cells,
such as glia and immune cells, and there is substantial evidence that
neuronal dysfunction can be caused by neuroinﬂammation [24,25].
Notably, treatment with minocycline, a tetracycline antibiotic that
exerts anti-inﬂammatory effects, rescued some FXS-related impair-
ments in Fmr1 knockout mice [26]. Neuroinﬂammation occurs in
response to brain injury, degenerating cells, insults, or infection, as
well as psychological stress, and is mediated by the immune resident
cells in the brain, microglia and astrocytes, as well as by inﬁltration of
peripheral immune cells [24,25,27]. Although a role for immune
responses and associated inﬂammation in autism is controversial [28–
30], there is some evidence of activated glia in autism [28,31–33] and
altered plasma cytokines associated with FXS [34]. However, little is
known about the immune system in Fmr1 knockout mice.
GSK3 represents a potential link between FXS and inﬂammation.
GSK3 is a partially constitutively active serine/threonine kinase that is
predominantly controlled by inhibitory serine phosphorylation of its
two isoforms, serine-9 in GSK3β and serine-21 in GSK3α [35–37].
Recently, we found that the inhibitory serine phosphorylation of both
GSK3 isoforms is decreased in several brain regions of Fmr1 knockout
mice compared with wild-type mice [13,20]. GSK3 has many
regulatory inﬂuences on the immune system [38], particularly
promoting inﬂammation both in the periphery [39] and in glia
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number of immune-mediated conditions in animal models, such as
septic shock ([39], reviewed in [42]). The present study extended the
examination of GSK3 serine phosphorylation to peripheral tissues,
and tested if the hyperactive GSK3 in Fmr1 knockout mice was
associated with changes in the peripheral or central immune systems
because GSK3 has widespread inﬂuences on immune function [38].
2. Materials and methods
2.1. Animals and in vivo tests
This study used adult, male C57Bl/6J littermates, ~3 months of age,
with or without a disruption of the Fmr1 gene (originally kindlyFig. 1. Reduced serine phosphorylation of GSK3α in the testis and liver of FX mice. Immunob
wild-type (WT) mice were probed with antibodies to (A and D) phospho-Ser21-GSK3α or
quantiﬁed by densitometry and values shown are the percentage of wild-type values. Means
(C) Testicular weights were measured from Fmr1 knockout mice and wild-type mice with an
untreated littermates. Means ± SEM; n=10 mice per group; *pb0.05 compared to wild-typrovided by Dr. W. Greenough, University of Illinois). The Fmr1
knockout mice were generated by breeding male C57BL/6J
hemizygous Fmr1 knockout mice and female C57BL/6J heterozy-
gous Fmr1 knockout mice to generate male homozygous Fmr1
knockout mice and wild-type littermates. Genotype was conﬁrmed
by PCR using the Jackson Laboratory protocol for genotyping Fmr1
mice. Mice were given water and food ad libitum. Lithium was
administered in pelleted food containing 0.2% lithium carbonate
(Harlan-Teklad) and mice were given 0.9% saline in addition to
water to prevent hyponatremia. Protein-free E. coli (K235) LPS was
prepared as described [39]. All mice were housed and treated in
accordance with National Institutes of Health and the University of
Alabama at Birmingham Institutional Animal Care and Use Committee
guidelines.lots of protein extracts from testis (A and B) or liver (D and E) of Fmr1 knockout (FX) or
total GSK3α, and (B and E) phospho-Ser9-GSK3β or total GSK3β. Immunoblots were
± SEM; n=5mice per group; *pb0.05 compared to wild-type values (Student's t-test).
d without lithium treatment between the ages of 12–16 weeks of age and compared to
pe, **pb0.05 compared to untreated (one-way ANOVA).
Fig. 2. Peripheral immune system is intact in FX mice. Flow cytometry was used to
identify cells from spleen and draining lymph nodes of Fmr1 knockout (FX) and wild-
type (WT) mice. (A) Surface expression of CD45 and CD11b was evaluated by
geographic mean intensity on cells from spleen and draining lymph nodes. (B) CD4+,
CD8+, and CD4+CD25 T cells are presented as a percentage of total cells. (C) Surface
expression of CD4, CD8, and CD25 wasmeasured on the respective T-cell populations as
evaluated by geographic mean intensity. n=5 mice per group.
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Cells obtained from lymph nodes or spleens were incubated with
anti-CD16/32 (FcR block, eBioscience) to prevent non-speciﬁc staining
and then stained for 30 min in the dark with anti-CD4-FITC, anti-CD8-
APC, and anti-CD25-PE or anti-CD45-FITC and anti-CD11b-Alexa647
(eBioscience). Stained cells were analyzed using a FACSCalibur and data
was analyzed using CellQuest software (BD Biosciences). The Cell Titer
96 AQueous One Solution Cell Proliferation Assay (Promega) was used
to measure cell proliferation according to the manufacturer's instruc-
tions. Primary microglia from Fmr1 knockout or wild-type mice were
prepared and cultured as described previously [40]. Primary microglia
were treated with 100 ng/mL LPS for 6 h followed by collection of the
media and measurements of cytokines. Fmr1 knockout or wild-type
mice were treated with LPS (10 mg/kg; i.p.) or vehicle (control) and
serum was collected after 4 h. Tumor necrosis factor-α (TNFalpha),
interleukin-6 (IL-6) and interferon-γ (IFNγ) were measured by
enzyme-linked immunosorbent assays (ELISA) according to manufac-
turer's instructions (eBioscience).
2.3. Tissue preparation and immunoblotting
Mice were decapitated, the brains rapidly frozen, and dissected
brain regions were homogenized in ice-cold lysis buffer containing
10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5%
NP-40, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 5 μg/ml pepstatin,
1 mM phenylmethanesulfonyl ﬂuoride, 1 mM sodium vanadate,
50 mM sodium ﬂuoride, and 100 nM okadaic acid. The lysates were
centrifuged at 20,000×g for 10 min to remove insoluble debris.
Protein concentrations in the supernatants were determined in
triplicate using the Bradford protein assay. Extracts were mixed
with Laemmli sample buffer (2% SDS) and placed in a boiling water
bath for 5 min. Proteins (10–20 μg) were resolved in SDS-polyacryl-
amide gels, and transferred to nitrocellulose. Blots were probed with
antibodies to phospho-Ser9-GSK3β, phospho-Ser21-GSK3α (Cell
Signaling Technology, Beverly, MA), total GSK3α/β, GFAP (Millipore,
Bedford, MA) and β-actin as a loading control (Sigma, St Louis, MO).
Immunoblots were developed using horseradish peroxidase-conju-
gated goat anti-mouse or goat anti-rabbit IgG (Bio-Rad Laboratories,
Hercules, CA), followed by detection with enhanced chemilumines-
cence, and quantitation by densitometry. To compare differences
between Fmr1 knockout and wild-type mice, values are shown as the
percents of densities of immunoblots of wild-type samples analyzed
on the same gels.
3. Results
3.1. GSK3 phosphorylation in testis and liver of Fmr1 knockout mice
We previously reported that the inhibitory serine phosphorylation
of both isoforms of GSK3 is lower in several brain regions of Fmr1
knockout mice than in wild-type mice [13,20]. We extended this
assessment to test if phosphorylation of GSK3 is also altered in testis
because although FMRP is expressed in all tissues, its highest levels of
expression are in neurons and testis [43], and Fmr1 knockout mice
display a macroorchidism phenotype. The serine phosphorylation of
GSK3α was signiﬁcantly ~40% lower in the testis of Fmr1 knockout
mice than wild-type mice (Fig. 1A). The serine phosphorylation of
GSK3β also tended to be ~40% lower, but this did not reach statistical
signiﬁcance because its very low level compared with GSK3α, as
reported previously [44], resulted in greater variability in the wild-
typemice (Fig. 1B). Therewas no difference in the total level of GSK3α
or GSK3β, indicating a deﬁcit in serine phosphorylation, not
expression, of GSK3 in testis of Fmr1 knockout mice. As reported
previously [10], testicular weight was greater in Fmr1 knockout mice
than in wild-type mice (Fig. 1C). Administration of the GSK3 inhibitorlithium for 4 weeks modestly, but signiﬁcantly, reduced testicular
weight in Fmr1 knockout mice treated between the ages of 12–
16 weeks, but had no effect in wild-type mice. The partial correction
of macroorchidism in Fmr1 knockout mice by lithium administration
suggests that GSK3 contributes to this phenotype.
To further examine tissue distribution of reduced serine phos-
phorylation of GSK3 in Fmr1 knockout mice, livers were examined. As
in the testis, phospho-Ser21-GSK3α was signiﬁcantly lower in the
liver of Fmr1 knockout mice (~25% reduction) than in wild-type mice,
with no difference in total levels of GSK3α (Fig. 1D). In contrast, there
was no difference in phospho-Ser9-GSK3β, or total GSK3β, in the liver
of Fmr1 knockout and wild-type mice (Fig. 1E). These results indicate
that the lack of FMRP contributes to impaired inhibitory serine
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FMRP contributes to maintaining inhibitory control of GSK3.3.2. Peripheral immune system of Fmr1 knockout mice
We evaluated several measures of basal immune system functions
in Fmr1 knockout mice because GSK3 has widespread regulatory
effects on the immune system [38] that may be altered by the
impaired inhibitory serine phosphorylation of GSK3 in central and
peripheral tissues of Fmr1 knockout mice and because immune
activation has been hypothesized to contribute to autism spectrum
disorders [28–30]. The immune system comprises early responders,
such as macrophages and dendritic cells, and a second line of defense
that includes T cells. Macrophages are characterized by the expression
of the surface markers CD45 and CD11b upon activation. There were
no difference in the expression of these two markers in spleen and
draining lymph node cells between Fmr1 knockout mice and wild-
type mice (Fig. 2A). Similarly, no differences were detected between
Fmr1 knockout and wild-type mice in the percentage of helper CD4+,
cytotoxic CD8+, or regulatory CD25+ T-cell populations (Fig. 2B), or in
the expression of the surface markers CD4, CD8 or CD25 in spleen or
draining lymph node cells (Fig. 2C). Consistent with this, proliferation
of T cells from spleen and draining lymph nodes in response to
stimulation with CD3 or a combination of CD3 and CD28 was not
different between Fmr1 knockout and wild-type mice (Fig. 3). Taken
together, these results indicate that there are not major alterations in
these components of the immune system in Fmr1 knockout mice.Fig. 3. Loss of FMRP does not alter proliferation of lymphocytes. Cells from (A) lymph
nodes or (B) spleen of Fmr1 knockout (FX) or wild-type (WT) mice were isolated and
stimulated with anti-CD3 or anti-CD3 with anti-CD28 antibodies for 72 h. Proliferation
was assessed using anMTS assay system as described inMaterials andmethods. Results
shown are means ± SEM; n=5 mice per group; *pb0.05, Student's t-test as compared
to untreated of the same genotype; **pb0.05, Student's t-test as compared to anti-CD3
of the same genotype.3.3. Cytokine response to LPS in Fmr1 knockout mice
To test if the production of cytokines is altered in Fmr1 knockout
mice, ELISA measurements were used to determine the serum levels
of the pro-inﬂammatory cytokines TNFα and IFNγ. Basal serum levels
of TNFα and IFNγ were low, and there were no differences between
Fmr1 knockout and wild-type mice (Fig. 4). In response to in vivo
administration of the bacterial endotoxin, lipopolysaccharide (LPS),
there were large increases in the serum levels of TNFα and IFNγ, and
the increases were equivalent in Fmr1 knockout and wild-type mice
(Fig. 4). However, examination of the time course of the responses of
these and other cytokines to LPS administrationwould provide amore
complete analysis.
3.4. FMRP expression in glia
Much of the research on Fmr1 knockout mice has focused on
neuronal function. However, FMRP is also expressed in astrocytes [45],
whichwe conﬁrmedusingprimary astrocytes cultures prepared from1-
day-old wild-type mice, although the level of FMRP was lower than in
primary hippocampal neurons (Fig. 5A). However, mouse primary
microglia and primary neural precursor cells express FMRP at levels
comparable to that of neurons (Fig. 5A). Themicroglial immunoblotwas
validated by staining FMRP in BV-2 microglial cells (Fig. 5B).
Since microglia express FMRP and are considered the macrophages
of the brain, we analyzed the production of the cytokines IL-6 and TNFα
by primary microglia prepared from Fmr1 knockout or wild-type mice.
Basal levels of IL-6 and TNFα were low in microglia from both Fmr1
knockout and wild-type mice (data not shown). Treatment with
100 ng/mL LPS for 6 h resulted in activation of microglia and large
increases in IL-6 and TNFα production, however no differences were
detected in microglia lacking FMRP (Fig. 5C). Thus, despite microglialFig. 4. LPS-induced production of TNFα and IFNγ is not altered in Fmr1 knockout mice.
Fmr1 knockout (FX) or wild-type (WT) mice were treated with LPS (10 mg/kg; i.p.) or
saline (control) and serum was collected after 4 h. TNFα (A) and IFNγ (B) levels were
measured by ELISA. Results are means ± SEM; n=8 mice per group.
Fig. 5. FMRP expression and microglia response to LPS. (A) Protein lysates were
prepared from cultured primary hippocampal neurons (Neu), primary astrocytes
(Astro), primary microglia (MG), and primary neuronal precursor cells (NPCs) derived
from brains of C57BL/6J wild-type mice. Immunoblots (10 μg protein) were probed
with anti-FMRP antibody. (B) Representative merged image of BV-2 microglia stained
with anti-FMRP antibody visualized under ﬂuorescence (red) and brightﬁeld (20×
magniﬁcation). (C) Cultured primary microglia from Fmr1 knockout (FX) or wild-type
(WT) mice were treated with 100 ng/mL LPS for 6 h followed by measurement of IL-6
and TNFα production by ELISA. Values from FX samples are presented as the percentage
of wild-type values; means ± SEM; n=8 mice per group.
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these two cytokines were not altered in cells deﬁcient in FMRP.Fig. 6. GFAP expression is increased in Fmr1 knockout mice and reduced by lithium
treatment. (A) Immunoblots of striatum (Str), hippocampus (Hip), cerebral cortex (Ctx),
and cerebellum (Cblm) extracts from Fmr1 knockout (FX) and wild-type (WT)mice were
probed with anti-GFAP antibody. Immunoblots were quantiﬁed by densitometry and are
presented as the percentage ofwild-type values analyzed on the same gels.Means±SEM;
n=8 mice per group; *pb0.05 compared to wild-type values (Student's t-test). Fmr1
knockout mice (B) and wild-type mice (C) were treated with lithium for 3–4 weeks and
compared to untreated littermates. Homogenates of the striatum (Str), hippocampus
(Hip), cerebral cortex (Ctx), and cerebellum(Cblm)wereprobedwith anti-GFAP antibody.
Immunoblotswerequantiﬁedbydensitometry and are presented as thepercents of values
from untreated mice. Means ± SEM; n=10 mice per group; *pb0.05 compared with
matched sample without lithium treatment.3.5. GFAP is increased in Fmr1 knockout mouse brain and reduced by
lithium
Increased GFAP expression is a hallmark characteristic of reactive
astrogliosis, a sign of inﬂammation in the brain, and increased astrocyte
reactivity has been reported in postmortem examination of brains from
patients with autism [33,46]. Immunoblots revealed that GFAP expres-
sion was signiﬁcantly up-regulated in the striatum, hippocampus, and
cerebral cortex of Fmr1 knockout mice compared to wild-type mice
(Fig. 6A). Since GSK3 promotes inﬂammatory reactions [38] and
administration of GSK3 inhibitors, such as lithium, rescue several
behavioral deﬁcits of Fmr1 knockout mice [13,20], we tested if lithium
treatment reversed the abnormally high levels of GFAP in Fmr1 knockout
mice. Chronic lithium treatment signiﬁcantly decreased GFAP levels in
the striatum and cerebellum of Fmr1 knockout mice (Fig. 6B) and also
reduced GFAP levels in several brain regions in wild-typemice (Fig. 6C).
This extends a previous report that lithium reduces LPS-induced up-
regulation of GFAP expression [40]. Taken together, this is the ﬁrst
evidenceof reactive astrocytes in Fmr1knockoutmiceanddemonstrates
that GFAP expression is reduced following lithium administration.
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Fmr1 knockout mice provide a model to study phenotypes
associated with FXS and autism and to examine responses to potential
therapeutic interventions [3–5,8,9]. Previously, we found lower
inhibitory serine phosphorylation of GSK3 in several brain regions
of Fmr1 knockout mice than wild-type mice, and this was implicated
as a contributory factor in several behavioral impairments because
they were ameliorated by administration of the GSK3 inhibitor
lithium [13,14,20]. In the present study, we tested if the loss of
FMRP resulted in changes in serine phosphorylation of GSK3 in
peripheral cells, as well as the brain, or altered the peripheral or
central immune systems. The results show that serine phosphoryla-
tion of GSK3α was lower in testis and liver of Fmr1 knockout mice
than wild-type mice, demonstrating that loss of FMRP can regulate
GSK3 phosphorylation in peripheral tissues as well as in the brain.
Furthermore, a functional effect of the hyperactive GSK3α in testis
was implicated by the ﬁnding that administration of the GSK3
inhibitor lithium reduced macroorchidism in Fmr1 knockout mice.
Although alterations in the peripheral immune system were not
found, Fmr1 knockout mice displayed signiﬁcantly increased astro-
gliosis compared to wild-typemice, and this was alleviated by lithium
administration, suggesting that GSK3 contributes to astrocyte activa-
tion in Fmr1 knockout mice.
Changes in the inhibitory serine phosphorylation are important
because this is the major mechanism for controlling the activity of
GSK3, and since GSK3 phosphorylates over 50 substrates, impairment
of this control mechanism can inﬂuence many cellular functions
[35,36,47]. The lower inhibitory serine phosphorylation of GSK3 in
brain regions of Fmr1 knockout mice compared with wild-type mice
[13,20] could result from altered neuronal activity regulating GSK3 in
Fmr1 knockout brains, or it could indicate a fundamental role for
FMRP in regulating intracellular signaling leading to serine phos-
phorylation of GSK3 that is lacking in Fmr1 knockoutmice. Evidence of
the latter mechanism, particularly for GSK3α, is indicated by the
lower phospho-Ser21-GSK3α in testis and liver in Fmr1 knockout
mice than wild-type mice. The possibility that GSK3α and GSK3β are
differentially inﬂuenced by FMRP in testis and liver is consistent with
growing evidence of different functions for the two GSK3 isoforms
[48]. The reduced inhibitory serine phosphorylation of testis GSK3 in
Fmr1 mice, indicative of increased GSK3 activity, appears to have a
contributory role in the macroorchidism that is characteristic of these
mice and of patients with FXS because chronic lithium treatment to
inhibit GSK3 signiﬁcantly reduced testicular weight in Fmr1 knockout
mice but not wild-type mice. Although the decreased testicular
weight in Fmr1 knockout mice after lithium treatment was modest, it
was achieved within 4 weeks of treatment, raising the possibility that
longer treatment would be even more effective. This adds a
morphological feature to the previously described behavioral char-
acteristics of Fmr1 knockout mice that are partially normalized by
lithium treatment.
GSK3 has many regulatory inﬂuences on immune function,
particularly promoting inﬂammation [38], and alterations in immune
system function have been suggested to contribute to the onset and/
or progression of ASDs [28–30]. Although few animal models of ASDs
exist, Fmr1 knockout mice exhibit some phenotypes characteristic of
ASDs [11–20]. Therefore, we examined if Fmr1 knockout mice display
signs of immune dysfunction or inﬂammation. T cells play a central
role in coordinating immune functions and mediate signaling
between the innate and adaptive immune systems. No alterations
were observed in the unchallenged peripheral immune system, in
LPS-stimulated production of TNFα or IFNγ, in T-cell numbers or
expression of cell surface markers in Fmr1 knockout mice. Thus, these
immune functions appear normal in Fmr1 knockout mice, although it
remains to be determined if other components of the peripheral
immune system are altered.In contrast to the apparently normal function of the peripheral
immune system, the central immune systemwas clearly affected by loss
of FMRP, as a signiﬁcant increase in the astrogliosis marker GFAP was
evident in the brains of Fmr1 knockout mice. GFAP is the most widely
used marker of astrocyte activation [49] and its up-regulation in Fmr1
knockout mouse brain is indicative of a chronic stress response. The
regional distribution of increased GFAP in Fmr1 knockout mice
(striatum, hippocampus, cerebral cortex, but not cerebellum) matched
the regional distributionof reduced inhibitory serinephosphorylationof
GSK3 in Fmr1 knockout mice on the C57Bl/6 background (striatum,
hippocampus, cerebral cortex, but not cerebellum) that we reported
previously [20]. This raised the possibility that the two may be related,
especially considering that GSK3 promotes activation of the STAT3
transcription factor that induces GFAP expression [50]. However,
although inhibition of GSK3 with lithium treatment occurred in all
four brain regions [20], lithiumadministration reducedGFAP levels only
in the striatum and cerebellum of Fmr1 knockout mice (Fig. 6B),
indicating that other factors besides hyperactive GSK3 promote
increased GFAP expression in Fmr1 knockout mice. Further studies of
the regulation of astrocyte activation and GFAP expression in FMRP-
knockout astrocytes should reveal the causes of astrogliosis in Fmr1
knockout mice. Since astrocytes are now well-known to regulate
neuronal function, it is possible that activated astrocytes contribute to
impaired neuronal activities in FXS. This is consistent with the recent
ﬁnding that astrocytes from Fmr1 knockout mice cultured with wild-
type hippocampal neurons caused abnormal neuronal morphologies,
and wild-type astrocytes ameliorated morphological impairments in
cultured FMRP-knockout neurons [51]. Although the causes and effects
of reactive astrocytes in the brains of Fmr1 knockout mice remain
questions to be addressed in further studies, the observed reduction of
GFAP expression by lithium treatment may contribute to its ameliora-
tion of behavioral abnormalities in these mice.
Loss of FMRP expression in FXS causes mental retardation and
characteristics of autism, but there are no satisfactory therapeutic
treatments. Recent research raised the possibility that lithiummay be
therapeutically useful in FXS [13,20,52,53]. Lithium is already used
therapeutically as a mood stabilizer, likely due to its inhibition of
GSK3, somuch is known about lithium's pharmacokinetics, safety, and
tolerability in humans [54]. Our current results show that lithium
rescues macroorchidism of Fmr1 knockout mice, which adds to the
previous ﬁndings of the beneﬁcial effects of lithium on behavioral
deﬁcits of Fmr1 knockout mice [13,20]. Furthermore, lithium
treatment also reduced GFAP levels, a marker of reactive astrogliosis,
in Fmr1 knockout mice, an action that may contribute to its
therapeutic actions on abnormal behaviors. These results demon-
strate that lithium does not only ameliorates neuronal-based
behaviors in Fmr1 knockout mice, but also attenuates abnormalities
in testis and astrocytes, lending further support to the proposal that
lithium may be beneﬁcial in patients with FXS and ASDs.
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